Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Atossa Genetics Inc. (ATOS : NSDQ)

• Company Description    Atossa Genetics Inc. is a healthcare company focused on the development and marketing of cellular and molecular diagnostic risk assessment products for breast cancer. The Company's diagnostic tests consist of medical devices which can collect fluid samples from the breast milk ducts. It is also conducting research on the treatment of pre-cancerous cells by using its FDA-cleared microcatheters to deliver, directly into the milk ducts, anti-cancer drugs that can be used to treat the pre-cancerous lesions. Atossa Genetics Inc. is headquartered in Seattle, WA. Number of Employees: 8

• Price / Volume Information    Yesterday's Closing Price: $0.96 Daily Weekly Monthly 20 Day Moving Average: 1,681,558 shares Shares Outstanding: 126.62 (millions) Market Capitalization: $121.48 (millions) Beta: 1.97 52 Week High: $9.80 52 Week Low: $0.88 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -8.63% 2.90% 12 Week -23.25% -15.63% Year To Date -40.04% -26.92%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 107 SPRING STREET - SEATTLE,WA 98104 USA ph: 206-325-6086 fax: 206-430-1288 scottg@coreir.com http://www.atossagenetics.com

• General Corporate Information    Officers Steven C. Quay - Chairman; Chief Executive Officer and President Kyle Guse - Chief Financial Officer; General Counsel and Secre Richard I. Steinhart - Director Shu-Chih Chen - Director Gregory Weaver - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED INSTRUMENTS Sector: Medical CUSIP: 04962H506 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/12/22 Share - Related Items Shares Outstanding: 126.62 Most Recent Split Date: 4.00 (0.08:1) Beta: 1.97 Market Capitalization: $121.48 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/12/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.90 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 0.00% vs. Previous Quarter: 0.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - -15.71 12/31/21 - -14.69 09/30/21 - -24.68 ROA 03/31/22 - -15.40 12/31/21 - -14.43 09/30/21 - -23.49 Current Ratio 03/31/22 - 58.94 12/31/21 - 45.18 09/30/21 - 85.31 Quick Ratio 03/31/22 - 58.94 12/31/21 - 45.18 09/30/21 - 85.31 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Book Value 03/31/22 - 1.06 12/31/21 - 1.09 09/30/21 - 1.11 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©